Bokf Na Decreases Stock Holdings in Amgen Inc. $AMGN

Key Points

• Bokf Na reduced its position in Amgen by 8.4% in Q4, selling 6,404 shares and now holds 69,470 shares valued at about $22.74 million.
• Amgen beat the recent quarter's estimates with $5.15 EPS versus $4.77 expected and $8.62 billion in revenue, and issued FY2026 guidance of 21.70–23.10 EPS (sell‑side consensus ~22.45).
• The company announced a quarterly dividend of $2.52 per share (annualized $10.08, ~3.1% yield; ex‑dividend May 15, payable June 5) and plans a $300 million U.S. manufacturing investment in Puerto Rico to expand biologics capacity.

Bokf Na lessened its position in shares of Amgen Inc. (NASDAQ:AMGN - Free Report) by 8.4% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 69,470 shares of the medical research company's stock after selling 6,404 shares during the quarter. Bokf Na's holdings in Amgen were worth $22,738,000 at the end of the most recent reporting period.

Other hedge funds also recently added to or reduced their stakes in the company. Robeco Institutional Asset Management B.V. raised its position in Amgen by 10.0% in the fourth quarter. Robeco Institutional Asset Management B.V. now owns 481,453 shares of the medical research company's stock valued at $157,584,000 after purchasing an additional 43,884 shares during the period. Sequoia Financial Advisors LLC raised its position in Amgen by 2.3% in the third quarter. Sequoia Financial Advisors LLC now owns 160,646 shares of the medical research company's stock valued at $45,334,000 after purchasing an additional 3,619 shares during the period. Curtis Advisory Group LLC purchased a new stake in Amgen in the fourth quarter valued at $1,669,000. Global Wealth Management Investment Advisory Inc. raised its position in Amgen by 56.2% in the third quarter. Global Wealth Management Investment Advisory Inc. now owns 13,056 shares of the medical research company's stock valued at $3,684,000 after purchasing an additional 4,699 shares during the period. Finally, Jones Financial Companies Lllp raised its position in Amgen by 18.2% in the third quarter. Jones Financial Companies Lllp now owns 39,778 shares of the medical research company's stock valued at $10,888,000 after purchasing an additional 6,115 shares during the period. 76.50% of the stock is currently owned by hedge funds and other institutional investors.

Amgen Trading Up 1.8%

AMGN opened at $329.59 on Wednesday. Amgen Inc. has a 12 month low of $261.43 and a 12 month high of $391.29. The stock has a market capitalization of $177.87 billion, a price-to-earnings ratio of 22.94, a PEG ratio of 3.08 and a beta of 0.44. The company has a debt-to-equity ratio of 5.65, a current ratio of 1.26 and a quick ratio of 0.90. The business has a fifty day moving average price of $357.16 and a 200 day moving average price of $341.35.

Amgen (NASDAQ:AMGN - Get Free Report) last released its earnings results on Thursday, April 30th. The medical research company reported $5.15 EPS for the quarter, topping the consensus estimate of $4.77 by $0.38. Amgen had a return on equity of 137.41% and a net margin of 20.96%.The firm had revenue of $8.62 billion during the quarter, compared to analysts' expectations of $8.58 billion. During the same period in the previous year, the firm posted $4.90 EPS. Amgen's revenue for the quarter was up 5.8% on a year-over-year basis. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. Sell-side analysts expect that Amgen Inc. will post 22.45 earnings per share for the current fiscal year.

Amgen Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, June 5th. Investors of record on Friday, May 15th will be paid a dividend of $2.52 per share. This represents a $10.08 annualized dividend and a yield of 3.1%. The ex-dividend date of this dividend is Friday, May 15th. Amgen's payout ratio is presently 70.15%.

Amgen News Summary

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Amgen announced a $300 million additional U.S. manufacturing investment (Puerto Rico) to expand biologics capacity and strengthen supply-chain resilience; investors tend to see such capital spending as supportive of long-term growth and reliability. Article Title
• Neutral Sentiment: Erste Group reaffirmed a "hold" rating on AMGN, signaling no change in near-term analyst conviction and limiting directional impact from that broker. Article Title
• Neutral Sentiment: Market/sector headwinds: healthcare stocks were softer in recent trading sessions, a background factor that can mute upside for AMGN even as company-specific news emerges. Article Title
• Negative Sentiment: Competitive risk: Viridian Therapeutics reported encouraging results for its chronic thyroid eye disease program, a potential rival to Amgen’s Tepezza — the data lifted Viridian shares and raises the probability of increased market competition for Tepezza sales over time. Article Title
• Negative Sentiment: Guggenheim trimmed its price target on AMGN to $340 (from $351) while keeping a Neutral rating — a modest lowering of upside that can cap near-term analyst-driven buying. Article Title

Wall Street Analyst Weigh In

AMGN has been the subject of several research reports. Erste Group Bank reiterated a "hold" rating on shares of Amgen in a report on Tuesday. Cantor Fitzgerald reiterated a "neutral" rating and issued a $350.00 target price on shares of Amgen in a report on Wednesday, April 8th. Morgan Stanley set a $332.00 target price on shares of Amgen in a report on Friday. UBS Group lifted their target price on shares of Amgen from $390.00 to $400.00 and gave the company a "buy" rating in a report on Monday, April 13th. Finally, Barclays initiated coverage on shares of Amgen in a report on Friday, February 20th. They issued an "equal weight" rating and a $350.00 target price for the company. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, fifteen have assigned a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of "Hold" and an average price target of $357.12.

Insider Buying and Selling

In related news, SVP Nancy A. Grygiel sold 1,237 shares of the business's stock in a transaction on Monday, May 4th. The shares were sold at an average price of $323.73, for a total transaction of $400,454.01. Following the completion of the transaction, the senior vice president owned 7,009 shares in the company, valued at approximately $2,269,023.57. The trade was a 15.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. 0.85% of the stock is owned by insiders.

Amgen Company Profile

Amgen Inc NASDAQ: AMGN is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen's work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen's commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.